eprintid: 578
rev_number: 9
eprint_status: archive
userid: 10
dir: disk0/00/00/05/78
datestamp: 2012-03-22 16:10:43
lastmod: 2015-05-29 20:12:05
status_changed: 2012-03-22 16:10:43
type: report
metadata_visibility: show
item_issues_count: 0
creators_name: D., Allwright
corp_creators: Richard Lyons
corp_creators: Rachel Russell
title: Interpreting pharmaceutical screening test results
ispublished: pub
subjects: medicine
studygroups: esgi80
companyname: Pfizer Worldwide R&D
full_text_status: public
abstract: In the pharmaceutical industry, compounds are tested for activity against
a disease target. In a High Throughput Assay (HTA), each compound is
tested at a single concentration. In an IC50 test, a compound is tested
at a range of concentrations. Sometimes there are discrepancies between
the results of these tests and the Study Group was asked to model this.
Rather than assume normally distributed errors in the percentage effect,
the Study Group proposed a model in which there are also probabilities
p and q of a test erroneously indicating very low or high activity. The
parameters p and q can be estimated from the data, and then can be
used in the design of testing procedures.
date: 2011
citation:   D., Allwright  (2011) Interpreting pharmaceutical screening test results.  [Study Group Report]     
document_url: http://miis.maths.ox.ac.uk/miis/578/1/6.pdf